Advanced search
Start date

Biosynthetic production of psilocybin and psilocin by Saccharomyces cerevisiae


Psilocybin is an alkaloid produced by the mushroom from the species Psylocibe cubensis. It has been reported that the applied microdose improves the treatment of several mental disorders, e.g.: anxiety, depression, addiction, and post-traumatic stress. In the past five years, the clinical utilization of psilocybin has been analyzed, and the high expectation of approval leads to the increase in this worldwide demand. Currently, biological extraction is the traditional way to get psilocybin, however, this method is susceptive to environmental variability, impairing the accumulation of the compound leading to the economic viability below the market expectations. On the other side, mushroom consumption "in natura" exposes the clinical user to wrong administration, hallucination and potential toxic effects. In this context, SynBD has developed a technological platform to obtain high purity and safe psilocybin and psilocin by bioproduction of the Saccharomyces cerevisiae microorganism. Based on the current success in the obtention of the prototype of biosynthetic psilocybin, the main goal of this project is to increase the production process on a large scale and high purity, aiming for the commercial viability of the international market represented by chemical and pharmaceutical companies. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list using this form.